KID syndrome with p.Asp50Asn mutation in GJB2

Authors

  • Macarena Nougues German Hospital of Buenos Aires, City of Buenos Aires, Argentina
  • Luciana L. Tirelli German Hospital of Buenos Aires, City of Buenos Aires, Argentina
  • Darío Macas German Hospital of Buenos Aires, City of Buenos Aires, Argentina
  • John McGrath St John’s Institute of Dermatology, London, England
  • Margarita Larralde German Hospital of Buenos Aires, City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/56fkkn36

Keywords:

KID syndrome, p.Asp50Asn mutation, GJB2, genodermatosis

Abstract

KID syndrome (keratitis, ichthyosis, deafness) is a rare genodermatosis with autosomal dominant inheritance, caused by mutations in the GJB2 gene encoding connexin 26. We report the case of a male patient clinically diagnosed in childhood, presenting with erythrokeratoderma, progressive vascularizing keratitis, and congenital sensorineural hearing loss. Genetic testing confirmed the p.Asp50Asn mutation in GJB2, the most common pathogenic variant associated with this condition. We describe the clinical features and complications, and discuss pathophysiological, genetic, and therapeutic aspects, including classical treatments and emerging molecular strategies under investigation.

Author Biographies

  • Macarena Nougues, German Hospital of Buenos Aires, City of Buenos Aires, Argentina

    Dermatology Resident

  • Luciana L. Tirelli, German Hospital of Buenos Aires, City of Buenos Aires, Argentina

    Staff Physician in Dermatology

  • Darío Macas, German Hospital of Buenos Aires, City of Buenos Aires, Argentina

    Dermatology Resident

  • John McGrath, St John’s Institute of Dermatology, London, England

    Head of the Department of Molecular Dermatology

  • Margarita Larralde, German Hospital of Buenos Aires, City of Buenos Aires, Argentina

    Head of Dermatology

References

I. Lilly E, Bunick C, Maley A, Zhang S, et al. More than keratitis, ichthyosis, and deafness: multisystem effects of lethal GJB2 mutations. J Am Acad Dermatol. 2019;80:617-625.

II. Cammarata-Scalisi F, Willoughby CE, Cárdenas-Tadich A, Labrador N, et al. Clinical, etiopathogenic, and therapeutic aspects of KID syndrome. Dermatol Ther. 2020; 33:e13507.

III. Asgari T, Naji M, Mansouri P, Mahmoudi H, et al. Keratitis-ichthyosis-deafness syndrome: phenotypic heterogeneity and treatment perspective of patients with p.Asp50Asn GJB2 mutation. Dermatol Ther. 2020; 33(6): e14493.

IV. Taki T, Takeichi T, Sugiura K, Akiyama M. Roles of aberrant hemichannel activities due to mutant connexin 26 in the pathogenesis of KID syndrome. Sci Rep. 2018; 8(1): 12824.

V. Rerknimitr P, Tanizaki H, Otsuka A, Miyachi Y, et al. Diminution of Langerhans cells in keratitis, ichthyosis, and deafness (KID) syndrome patient with recalcitrant cutaneous candidiasis. J Eur Acad Dermatol Venereol. 2016; 30(2): e47-e49.

VI. Coggshall K, Farsani T, Ruben B, McCalmont T, et al. Keratitis, ichthyosis, and deafness (KID) syndrome: a review of infectious and neoplastic complications. J Am Acad Dermatol. 2013; 69(1): 127-134.e3.

VII. Patel V, Sun G, Dickman M, Khuu P, et al. Treatment of keratitis-ichthyosis- deafness (KID) syndrome in children: a case report and review of the literature. Dermatol Ther. 2015;28(2):89–93.

VIII. Wolfe CM, Davis A, Shaath TS, Cohen GF. Visual impairment reversal with oral acitretin therapy in keratitis-ichthyosis-deafness (KID) syndrome. JAAD Case Rep. 2017;3:556–558.

IX. Sellitto C, Li L, White T. Connexin hemichannel inhibition ameliorates epidermal pathology in a mouse model of keratitis ichthyosis deafness syndrome. Sci Rep. 2021; 11: 24118.

X. Lee MY, Wang HZ, White TW, Brooks T, et al. Allele-specific small interfering RNA corrects aberrant cellular phenotype in keratitis-ichthyosis-deafness syndrome keratinocytes. J Invest Dermatol. 2020;140:1035-1044.

Downloads

Published

2026-04-28

Issue

Section

Clinical Cases